scholarly journals CDK4/6 inhibitors in advanced breast cancer, what is beyond?

2019 ◽  
Vol 13 (2) ◽  
Author(s):  
Amrallah A. Mohammed ◽  
Hanaa Rashied ◽  
Fifi Mostafa Elsayed
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hormonal Treatment ◽  
Advanced Breast ◽  
Mechanisms Of Resistance ◽  
Clinical Challenge

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.

scholarly journals The role of abemaciclib in treatment of advanced breast cancer

2018 ◽  
Vol 10 ◽  
pp. 175883591877692 ◽  
Author(s):  
Amelia McCartney ◽  
Erica Moretti ◽  
Giuseppina Sanna ◽  
Marta Pestrin ◽  
Emanuela Risi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Single Agent ◽  
Endocrine Resistance ◽  
Predictive Biomarkers ◽  
Progression Free Survival ◽  
Advanced Breast ◽  
Significant Activity ◽  
Epidermal Growth

Until recently, the mainstay of treatment in the majority of hormone receptor (HR)-positive, human epidermal growth factor 2 receptor (HER2)-negative advanced breast cancer (ABC) has consisted of single-agent endocrine therapy (ET). However, as understanding of endocrine resistance has grown, newer targeted agents have come to the fore. Inhibition of cyclin-dependent kinase complexes 4 and 6 (CDK4/6) combined with ET has shown significant activity in HR+ HER2− ABC, with impressive results in terms of progression-free survival (PFS) when compared with ET alone. This review summarizes the seminal findings pertaining to CDK4/6 inhibition in this population, specifically focusing on abemaciclib, contrasted with palbociclib and ribociclib. Potential directions for future studies are discussed, as a way of addressing outstanding issues such as establishing optimal treatment sequencing and agent combinations, appropriate patient selection to derive maximal benefits, predictive biomarkers and the employment of CDK4/6 inhibition beyond the ABC setting.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

2004 ◽  
Vol 31 ◽  
pp. 106-146 ◽  
Author(s):  
Nicholas J. Robert ◽  
Charles L. Vogel ◽  
I. Craig Henderson ◽  
Joseph A. Sparano ◽  
Melvin R. Moore ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Systemic Therapies
Sign in / Sign up

Export Citation Format

Share Document